{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antithrombotic+treatment&page=2", "query": { "intervention": "Antithrombotic treatment", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 28, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antithrombotic+treatment&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Antithrombotic+treatment&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T12:38:33.418Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03288441", "title": "Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hematologic Neoplasms", "Thrombocytopenia", "Anticoagulants", "Platelet Aggregation Inhibitors" ], "interventions": [ { "name": "Hold", "type": "DRUG" }, { "name": "Prophylactic dose antithrombotic", "type": "DRUG" }, { "name": "Change antithrombotic Drug", "type": "DRUG" }, { "name": "Change platelet transfusion threshold", "type": "BIOLOGICAL" }, { "name": "Full dose antithrombotics", "type": "DRUG" }, { "name": "Mechanical measures", "type": "DEVICE" }, { "name": "Intermediate dose antithrombotic", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "DEVICE" ], "sponsor": "Maastricht University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2018-03-20", "completion_date": "2021-12-31", "has_results": false, "last_update_posted_date": "2020-09-17", "last_synced_at": "2026-10-05T12:38:33.418Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03288441" }, { "nct_id": "NCT00625248", "title": "Prospective Evaluation of Bleeding Risk of Anticoagulant and Anti-platelet Therapy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Bleeding" ], "interventions": [ { "name": "Antithrombotics", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pain Management Center of Paducah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12000, "start_date": "2008-02", "completion_date": "2010-01", "has_results": false, "last_update_posted_date": "2013-06-24", "last_synced_at": "2026-10-05T12:38:33.418Z", "location_count": 1, "location_summary": "Paducah, Kentucky", "locations": [ { "city": "Paducah", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT00625248" }, { "nct_id": "NCT03950076", "title": "EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Intracranial Hemorrhages", "Atrial Fibrillation" ], "interventions": [ { "name": "Edoxaban", "type": "DRUG" }, { "name": "Non-anticoagulant medical therapy", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Population Health Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": null, "sex": "ALL", "summary": "45 Years and older" }, "enrollment_count": 948, "start_date": "2019-09-20", "completion_date": "2026-07-22", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-10-05T12:38:33.418Z", "location_count": 10, "location_summary": "Elk Grove Village, Illinois • Lisle, Illinois • New Orleans, Louisiana + 7 more", "locations": [ { "city": "Elk Grove Village", "state": "Illinois" }, { "city": "Lisle", "state": "Illinois" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Queens", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03950076" }, { "nct_id": "NCT05848713", "title": "AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Community-acquired Pneumonia" ], "interventions": [ { "name": "Heparin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Manitoba", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4000, "start_date": "2023-10-10", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-05T12:38:33.418Z", "location_count": 6, "location_summary": "Chicago, Illinois • Jefferson, Louisiana • Portland, Maine + 3 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Jefferson", "state": "Louisiana" }, { "city": "Portland", "state": "Maine" }, { "city": "Dearborn", "state": "Michigan" }, { "city": "Camden", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05848713" }, { "nct_id": "NCT00628498", "title": "Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatic Veno-Occlusive Disease" ], "interventions": [ { "name": "Defibrotide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1206, "start_date": "2007-12", "completion_date": "2016-09", "has_results": true, "last_update_posted_date": "2017-11-30", "last_synced_at": "2026-10-05T12:38:33.418Z", "location_count": 125, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 87 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00628498" }, { "nct_id": "NCT02319460", "title": "An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hemorrhage" ], "interventions": [ { "name": "Kcentra®", "type": "BIOLOGICAL" }, { "name": "Plasma", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "CSL Behring", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2238, "start_date": "2014-04-24", "completion_date": "2020-06-30", "has_results": false, "last_update_posted_date": "2021-05-26", "last_synced_at": "2026-10-05T12:38:33.418Z", "location_count": 1, "location_summary": "Oakland, California", "locations": [ { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02319460" }, { "nct_id": "NCT03698513", "title": "A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "BMS-986177", "type": "DRUG" }, { "name": "Placebo (for BMS-986177)", "type": "OTHER" }, { "name": "Clopidogrel", "type": "DRUG" }, { "name": "Aspirin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 113, "start_date": "2018-10-04", "completion_date": "2019-02-19", "has_results": false, "last_update_posted_date": "2021-09-29", "last_synced_at": "2026-10-05T12:38:33.418Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03698513" }, { "nct_id": "NCT04505774", "title": "Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Covid19" ], "interventions": [ { "name": "theraputic heparin", "type": "DRUG" }, { "name": "prophylactic heparin", "type": "DRUG" }, { "name": "P2Y12", "type": "DRUG" }, { "name": "Crizanlizumab Injection", "type": "DRUG" }, { "name": "SGLT2 inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Matthew Neal MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3591, "start_date": "2020-09-04", "completion_date": "2024-01-26", "has_results": true, "last_update_posted_date": "2024-12-30", "last_synced_at": "2026-10-05T12:38:33.418Z", "location_count": 81, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 65 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fontana", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04505774" }, { "nct_id": "NCT00859885", "title": "International PFO Consortium", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Stroke", "Transient Ischemic Attack" ], "interventions": [ { "name": "Antithrombotic treatment", "type": "DRUG" }, { "name": "percutaneous device closure of PFO", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Insel Gruppe AG, University Hospital Bern", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1500, "start_date": "2008-09-08", "completion_date": "2021-12", "has_results": false, "last_update_posted_date": "2017-12-12", "last_synced_at": "2026-10-05T12:38:33.418Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Springfield, Massachusetts • Tyler, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Springfield", "state": "Massachusetts" }, { "city": "Tyler", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00859885" }, { "nct_id": "NCT02164864", "title": "Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation", "Percutaneous Coronary Intervention" ], "interventions": [ { "name": "Dabigatran Etexilate 110mg", "type": "DRUG" }, { "name": "Warfarin 3mg", "type": "DRUG" }, { "name": "Aspirin", "type": "DRUG" }, { "name": "Dabigatran Etexilate 150mg", "type": "DRUG" }, { "name": "Clopidogrel or Ticagrelor", "type": "DRUG" }, { "name": "Warfarin 5mg", "type": "DRUG" }, { "name": "Warfarin 1mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2725, "start_date": "2014-07-22", "completion_date": "2017-06-05", "has_results": true, "last_update_posted_date": "2018-07-31", "last_synced_at": "2026-10-05T12:38:33.418Z", "location_count": 45, "location_summary": "Birmingham, Alabama • Cottonwood, Arizona • Mesa, Arizona + 41 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Cottonwood", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02164864" } ] }